The Wren PROSTest is a 27-gene blood biopsy biomarker delivering greater than 90% accuracy in diagnosing and monitoring prostate cancer.
This study demonstrates sensitivity and specificity benefits of a blood-based multianalyte NET gene transcript measurement to detect GI tract cancer.
A critical requirement in neuroendocrine tumor (NET) management is a blood biomarker test that is sensitive, specific and reproducible. Recent research indicates that NETest, a 51 panel multigene blood transcript analysis, is significantly more sensitive and efficient (>93%) than any single analyte assay (CgA, PST or NKA) for NET detection in a prospectively collected age and sex matched sample set of NETs and controls.
A critical requirement in neuroendocrine tumor (NET) management is a sensitive, specific and reproducible blood biomarker test. Research shows NETest was >92% accurate, while CgA was 76% accurate, PST 63% accurate and NKA 39% accurate.
The clinical utility of a novel blood-based multi-transcriptome assay for gastrointestinal tract NET diagnosis
This study demonstrates that a blood-based multianalyte NET gene transcript measurement of well-differentiated small intestinal and pancreatic NET disease is sensitive (94-98%) and specific, and outperforms the current monoanalyte diagnostic strategy of plasma CgA (52%) measurement.
The clinical utility of circulating neuroendocrine gene transcript analysis in well-differentiated paragangliomas and pheochromocytomas
PPGLs exhibit variable malignancy, which is difficult to determine by histopathology, amine measurements or tissue genetic analyses. Circulating NET transcript analysis is positive (100% diagnostic) in well-differentiated PCC/PGL, scores were elevated in progressive disease irrespective of mutation or biochemical activity and elevated levels were prognostic.
Blood Neuroendocrine Gene Transcript Measurement Utility in BPNET Diagnosis, Surgical Resection and Disease Progression Evaluation
Current biomarkers used in broncopulmonary neuroendocrine tumor management are single analytes and have a low utility, e.g., CgA (Chromogranin A) or NSE (neuron specific enolase). Blood NET gene levels accurately identified BPNETs (100%) and differentiated these from controls, benign and malignant lung disease.